Inotuzumab Ozogamicin + Vincristine Sulfate Liposome
Phase 1/2WithdrawnDevelopment Stage
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Jan 21, 2021 → Jan 21, 2024
About Inotuzumab Ozogamicin + Vincristine Sulfate Liposome
Inotuzumab Ozogamicin + Vincristine Sulfate Liposome is a phase 1/2 stage product being developed by Pfizer for Allogeneic Hematopoietic Stem Cell Transplantation Recipient. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03851081. Target conditions include Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03851081 | Phase 1/2 | Withdrawn |
Competing Products
9 competing products in Allogeneic Hematopoietic Stem Cell Transplantation Recipient
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP0113 | Astellas Pharma | Phase 2 | 52 |
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 77 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar | Pfizer | Phase 3 | 76 |
| Genotropin (Recombinant Human Growth Hormone) | Pfizer | Phase 1 | 32 |
| immunosuppression | Pfizer | Phase 2 | 51 |
| Mycophenolate Mofetil | Hikma Pharmaceuticals | Pre-clinical | 18 |
| Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo | Seres Therapeutics | Phase 1 | 25 |